AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

ClinicalTrials.gov ID

NCT07697391

Lead Sponsor

The First Affiliated Hospital of Anhui Medical UniversityOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

285Estimated

Last Update Posted

Jul 13, 2026Actual

Start Date

Jul 20, 2026Estimated

Primary Completion Date

Oct 31, 2027Estimated

Completion Date

Jan 31, 2028Estimated

Official Title

A Multicenter Randomized Controlled Trial Evaluating AI-Assisted Intensive Lifestyle Intervention Versus Tirzepatide for Glycemic and Weight Management in Patients With Obesity and Newly Diagnosed Type 2 Diabetes

Brief Summary

This multicenter randomized controlled trial will evaluate whether an AI-assisted intensive lifestyle intervention can improve weight and glycemic management in adults with obesity and newly diagnosed type 2 diabetes, compared with tirzepatide treatment and standard lifestyle management. Eligible participants will be adults aged 18 to 65 years with a body mass index of 28 to less than 40 kg/m² and newly diagnosed type 2 diabetes who have not used glucose-lowering medications in the past 3 months.

Participants will be randomly assigned to one of three groups: an AI-assisted intensive lifestyle intervention group, a tirzepatide treatment group, or a standard lifestyle management control group. The intervention period will last 52 weeks, followed by a 12-week post-intervention follow-up period. The main outcome is the percentage change in body weight at week 52. The study will also assess glycemic control, body composition, continuous glucose monitoring metrics, safety, and other metabolic outcomes.

• Obesity
• Diabetes Mellitus, Type 2

• AI-Assisted Intensive Lifestyle Intervention
• Tirzepatide
• Standard Lifestyle Management

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Male or female participants aged 18 to 65 years.
2. Newly diagnosed type 2 diabetes mellitus, defined as diagnosis within 3 years and no use of glucose-lowering medications within the past 3 months. Diagnosis should meet the 1999 World Health Organization criteria, including at least one of the following: random plasma glucose ≥11.1 mmol/L, fasting blood glucose ≥7.0 mmol/L, 2-hour postprandial blood glucose ≥11.1 mmol/L, or HbA1c ≥6.5% and ≤10.0%. Participants without typical diabetes symptoms should have repeat testing for confirmation.
3. Body mass index ≥28 kg/m² and <40 kg/m².
4. Willing to use effective contraception and have no pregnancy plan within 12 months after signing the informed consent form; female participants must have a negative pregnancy test at screening.
5. Able to communicate with the investigators, willing to comply with the study protocol, and voluntarily sign the informed consent form.

Exclusion Criteria:

1. Type 1 diabetes mellitus, type 2 diabetes requiring insulin treatment, or other specific types of diabetes.
2. Body weight change >5% within 12 weeks before screening.
3. Pregnant or breastfeeding women.
4. Severe trauma, severe infection, or surgery within 1 month before screening that may affect glycemic control.
5. Severe cardiovascular or cerebrovascular events within 6 months before screening, including angina, myocardial infarction, arrhythmia, cerebral infarction, cerebral hemorrhage, or other clinically significant events.
6. History of acute or chronic pancreatitis, history of pancreatic injury, or amylase >1.5 × upper limit of normal at screening.
7. Current or previous malignancy, except local basal cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the prostate; diagnosis of malignancy within 5 years before screening.
8. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or history of thyroid nodules.
9. Blood dyscrasia or any disease causing hemolysis or unstable red blood cells, or hemoglobinopathy that may affect HbA1c measurement.
10. History of organ transplantation or acquired or congenital immune system disease.
11. Schizophrenia or other psychiatric disorder that may interfere with participation in the study.
12. Unstable or treatment-requiring endocrine disease related to glycemic control, such as hyperthyroidism, acromegaly, or Cushing syndrome, as judged by the investigator.
13. Hypertension with systolic blood pressure >150 mmHg and/or diastolic blood pressure >90 mmHg after stable antihypertensive treatment.
14. Clinically significant abnormal gastric emptying, severe chronic gastrointestinal disease, diabetic gastroparesis, long-term use of medications directly affecting gastrointestinal motility, or history of gastrointestinal surgery.
15. Special dietary requirements or allergy to foods such as soy products or dairy products.
16. Use of medications affecting glucose regulation within 3 months before randomization, such as glucocorticoids, growth hormone, thyroid hormone, sex hormones, cyclosporine, or phenytoin.
17. Allergic constitution, defined as allergy to two or more categories of substances.
18. Fasting C-peptide <0.81 ng/mL.
19. Calcitonin ≥50 pg/mL.
20. Abnormal laboratory results, including AST or ALT >2.5 × upper limit of normal, bilirubin >2.5 × upper limit of normal, triglycerides ≥5.7 mmol/L, estimated creatinine clearance <60 mL/min using the Cockcroft-Gault formula, or clinically significant anemia with hemoglobin <120 g/L in men or <110 g/L in women.
21. Unstable proliferative retinopathy or maculopathy requiring urgent treatment within 1 year before randomization, or history of diabetic ketoacidosis, hyperosmolar nonketotic coma, or severe metabolic disorder causing neuropsychiatric dysfunction.
22. History or risk factors of epilepsy, syncope, cardiac arrest, arrhythmia, atrioventricular block, structural heart disease, torsades de pointes, hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia, or hypocalcemia.
23. Active bacterial, viral, or fungal infection requiring hospitalization or intravenous antibiotic treatment.
24. Positive HBsAg, HCV antibody, HIV antibody, or Treponema pallidum antibody.
25. Positive urine drug screening and/or drug dependence.
26. Participation in another clinical trial within 3 months before enrollment or current participation in another drug or device clinical trial.
27. Any other condition that, in the investigator's opinion, makes the participant unsuitable for this study.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

The First Affiliated Hospital of Anhui Medical UniversityOTHER

Collaborators

Zhejiang Nutriease Health Technology Co. Ltd.INDUSTRY

hemeiwen0128@163.com+8619966188536

• AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

  NCT07555730

  Not yet recruitingInterventionalPhase 4Updated Apr 29, 2026
• Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

  NCT06180616

  Not yet recruitingInterventionalPhase 2Updated Jul 29, 2025
• Intensive Diet and Physical Activity on Diabetes

  NCT03839667

  Active, not recruitingInterventionalNot ApplicableUpdated Feb 12, 2026
• T2DM Intensity Lifestyle Intervention

  NCT05561855

  CompletedInterventionalNot ApplicableUpdated Nov 18, 2023
• Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

  NCT06009653

  WithdrawnInterventionalPhase 4Updated Feb 25, 2025
• A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

  NCT06962280

  Active, not recruitingInterventionalPhase 3Updated Feb 17, 2026